CD19-CAR T-cell therapy induces deep tissue depletion of B cellsCarlo Tur, Maria Gabriella Raimondo, Andréas Mackensen et al.|Annals of the Rheumatic Diseases|2024Cited by 150
Bispecific T cell engager therapy for refractory rheumatoid arthritisLaura Bucci, Ricardo Grieshaber‐Bouyer, Melanie Hagen et al.|Nature Medicine|2024Cited by 147
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case seriesJanina Auth, Christina Bergmann, Fabian Müller et al.|The Lancet Rheumatology|2024Cited by 96
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, Laura S. Mertens et al.|European Urology|2020Cited by 89
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsFabian Müller, Ricardo Grieshaber‐Bouyer, Andreas Wirsching et al.|Nature Medicine|2025Cited by 60